Nothing Special   »   [go: up one dir, main page]

MX356891B - Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos. - Google Patents

Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.

Info

Publication number
MX356891B
MX356891B MX2014014689A MX2014014689A MX356891B MX 356891 B MX356891 B MX 356891B MX 2014014689 A MX2014014689 A MX 2014014689A MX 2014014689 A MX2014014689 A MX 2014014689A MX 356891 B MX356891 B MX 356891B
Authority
MX
Mexico
Prior art keywords
antiviral therapy
hiv
combinations
treatment
aids
Prior art date
Application number
MX2014014689A
Other languages
English (en)
Inventor
Richard Underwood Mark
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356891(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of MX356891B publication Critical patent/MX356891B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a combinaciones de los compuestos que comprenden inhibidores de la integrasa de VIH yotros agentes terapéuticos. Estas combinaciones son útiles en la inhibición de la réplica del VIH, la prevención y/o el tratamiento de la infección por VIH, y en el tratamiento de SIDA y/o ARC.
MX2014014689A 2010-01-27 2011-01-24 Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos. MX356891B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (1)

Publication Number Publication Date
MX356891B true MX356891B (es) 2018-06-19

Family

ID=44319704

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014014689A MX356891B (es) 2010-01-27 2011-01-24 Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.
MX2012008774A MX2012008774A (es) 2010-01-27 2011-01-24 Terapia antiviral.
MX2014014688A MX367937B (es) 2010-01-27 2011-01-24 Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.
MX2014014687A MX367938B (es) 2010-01-27 2011-01-24 Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2012008774A MX2012008774A (es) 2010-01-27 2011-01-24 Terapia antiviral.
MX2014014688A MX367937B (es) 2010-01-27 2011-01-24 Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.
MX2014014687A MX367938B (es) 2010-01-27 2011-01-24 Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.

Country Status (45)

Country Link
US (12) US20120295898A1 (es)
EP (6) EP3127542B1 (es)
JP (8) JP2013518107A (es)
KR (4) KR101964923B1 (es)
CN (2) CN105311033B (es)
AP (1) AP3551A (es)
AU (1) AU2011209788C1 (es)
BR (1) BR112012018670A2 (es)
CA (4) CA3060290C (es)
CL (1) CL2012002080A1 (es)
CO (1) CO6602152A2 (es)
CR (1) CR20120423A (es)
CY (4) CY1116509T1 (es)
DK (4) DK3494972T3 (es)
DO (2) DOP2012000205A (es)
EA (4) EA037601B1 (es)
EC (1) ECSP12012106A (es)
ES (4) ES2969969T3 (es)
FI (2) FI3494972T3 (es)
FR (2) FR18C1043I2 (es)
HK (3) HK1209629A1 (es)
HR (4) HRP20240168T1 (es)
HU (6) HUE026849T2 (es)
IL (5) IL221007A (es)
LT (4) LT3127542T (es)
LU (1) LUC00090I2 (es)
MA (1) MA34002B1 (es)
ME (2) ME02182B (es)
MX (4) MX356891B (es)
MY (2) MY188334A (es)
NO (2) NO2932970T3 (es)
NZ (4) NZ627824A (es)
PE (2) PE20160180A1 (es)
PH (2) PH12016500195B1 (es)
PL (4) PL2932970T3 (es)
PT (4) PT3127542T (es)
RS (4) RS57728B1 (es)
SG (3) SG10201509476RA (es)
SI (4) SI2932970T1 (es)
SM (1) SMT201500177B (es)
TN (1) TN2012000376A1 (es)
TR (1) TR201807704T4 (es)
UA (1) UA105556C2 (es)
WO (1) WO2011094150A1 (es)
ZA (1) ZA201205586B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037601B1 (ru) 2010-01-27 2021-04-20 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
NZ706223A (en) 2012-10-23 2018-11-30 Cipla Ltd Pharmaceutical antiretroviral composition
EA037633B1 (ru) 2012-12-21 2021-04-23 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en) 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (es) 2013-07-12 2018-07-21
EA030695B1 (ru) 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
EP3151920A4 (en) 2014-06-04 2017-12-27 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016016279A1 (en) 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
BR112017020837A2 (pt) 2015-04-02 2018-07-03 Gilead Sciences, Inc. compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
EP3334419A1 (en) * 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
JP7384783B2 (ja) 2017-07-21 2023-11-21 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
WO2019016760A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES AND PREPARATIONS FOR THE TREATMENT OF HIV INFECTIONS AND AIDS
KR20200070246A (ko) * 2017-10-13 2020-06-17 비이브 헬쓰케어 컴퍼니 이중층 제약 정제 제제
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
BR112022013452A2 (pt) * 2020-01-09 2022-09-13 Univ Washington Combinações de agentes terapêuticos de ação prolongada e métodos das mesmas
CA3166480A1 (en) 2020-02-24 2021-09-02 Lan Jiang Tetracyclic compounds for treating hiv infection
HRP20231654T1 (hr) 2021-01-19 2024-03-15 Gilead Sciences, Inc. Supstituirani spojevi piridotriazina i njihove uporabe
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
CO4900074A1 (es) * 1996-06-25 2000-03-27 Glaxo Group Ltd Combinaciones antivirales
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
PL201632B1 (pl) 2000-01-31 2009-04-30 Cook Biotech Zespół zastawki stentu
NZ529403A (en) 2001-04-10 2005-06-24 Pfizer Pyrazole derivatives for treating HIV
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
WO2004002433A1 (en) 2002-06-27 2004-01-08 Medivir Ab Synergistic interaction of abacavir and alovudine
AU2004206827A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US8691991B2 (en) * 2004-02-11 2014-04-08 Shionogi & Co., Ltd. 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
CA2562713A1 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR20090120011A (ko) 2004-08-23 2009-11-23 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
EP3284520B1 (en) 2005-04-28 2019-06-05 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2008542352A (ja) 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
AU2006332664B2 (en) * 2005-12-30 2013-03-14 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of HIV integrase inhibitors
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
BRPI0707179A2 (pt) * 2006-01-20 2011-04-26 Tibotec Pharm Ltd tratamento de longo termo de infecção por hiv
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
JP5599611B2 (ja) 2006-07-21 2014-10-01 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルスプロテアーゼインヒビター
MX2009003410A (es) 2006-09-29 2009-07-17 Idenix Pharmaceuticals Inc Fosfoindoles enantiomericamente puros como inhibidores de vih.
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
SG183059A1 (en) 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
TW200918507A (en) 2007-06-29 2009-05-01 Gilead Sciences Inc Novel HIV reverse transcriptase inhibitors
AR067412A1 (es) 2007-07-06 2009-10-07 Gilead Sciences Inc Moduladores de propiedades farmaceuticas de productos terapeuticos
RU2498979C2 (ru) * 2007-07-12 2013-11-20 Тиботек Фармасьютикалз Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
US8466177B2 (en) 2007-11-01 2013-06-18 The Uab Research Foundation Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
AU2008342537A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
CN101977924A (zh) 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
WO2009088719A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
PT2320908E (pt) * 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
ES2641765T3 (es) * 2008-12-11 2017-11-13 Shionogi & Co., Ltd. Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
EA037601B1 (ru) 2010-01-27 2021-04-20 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
CA2832066C (en) 2011-04-01 2023-04-18 The Medicines Company Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
CL2012002080A1 (es) 2012-11-30
DOP2021000147A (es) 2022-01-16
CN105311033A (zh) 2016-02-10
US20120295898A1 (en) 2012-11-22
LTC2932970I2 (lt) 2022-04-25
CN102791129B (zh) 2015-09-30
US10426780B2 (en) 2019-10-01
CY1116509T1 (el) 2017-03-15
KR20180078358A (ko) 2018-07-09
DK2531027T3 (en) 2015-07-20
JP2016145204A (ja) 2016-08-12
HK1250335A1 (zh) 2018-12-14
RS57728B1 (sr) 2018-12-31
MY202778A (en) 2024-05-21
HUS2400017I1 (hu) 2024-06-28
CN102791129A (zh) 2012-11-21
JP2021091705A (ja) 2021-06-17
US20210401850A1 (en) 2021-12-30
JP6268386B2 (ja) 2018-01-31
EA201892277A1 (ru) 2019-03-29
HUE065569T2 (hu) 2024-06-28
SG10201707183TA (en) 2017-10-30
IL257267A (en) 2018-03-29
ZA201205586B (en) 2014-01-29
EA032868B1 (ru) 2019-07-31
IL245182B (en) 2018-04-30
EP2531027A1 (en) 2012-12-12
PL2932970T3 (pl) 2018-08-31
CA3060290C (en) 2022-07-12
SI3127542T1 (sl) 2018-11-30
CY2018029I1 (el) 2019-07-10
MX2012008774A (es) 2012-08-17
WO2011094150A1 (en) 2011-08-04
ES2543066T3 (es) 2015-08-14
PT2932970T (pt) 2018-06-08
PL3127542T3 (pl) 2019-03-29
CA2787691A1 (en) 2011-08-04
ES2688925T3 (es) 2018-11-07
ES2670811T3 (es) 2018-06-01
HUE040554T2 (hu) 2019-03-28
KR20160111536A (ko) 2016-09-26
NZ627826A (en) 2016-01-29
EP4316599A3 (en) 2024-04-10
CA3003988C (en) 2020-01-07
US11234985B2 (en) 2022-02-01
EP2932970B1 (en) 2018-03-21
HRP20180855T1 (hr) 2018-06-29
US20170216284A1 (en) 2017-08-03
UA105556C2 (uk) 2014-05-26
PL3494972T3 (pl) 2024-05-27
EA025176B1 (ru) 2016-11-30
HK1179522A1 (en) 2013-10-04
EA201690872A2 (ru) 2016-08-31
IL245182A0 (en) 2016-06-30
EP2932970A1 (en) 2015-10-21
EA201690872A3 (ru) 2016-12-30
DK3494972T3 (da) 2024-01-29
SI2932970T1 (en) 2018-07-31
CA2967453A1 (en) 2011-08-04
JP2023085431A (ja) 2023-06-20
KR20120128640A (ko) 2012-11-27
JP2019167371A (ja) 2019-10-03
AP2012006445A0 (en) 2012-08-31
HRP20181531T1 (hr) 2018-11-16
NZ627824A (en) 2016-02-26
JP2022071126A (ja) 2022-05-13
PL2531027T3 (pl) 2016-01-29
IL221007A0 (en) 2012-09-24
AP3551A (en) 2016-01-18
HUE026849T2 (en) 2016-08-29
HUE037812T2 (hu) 2018-09-28
DK3127542T3 (en) 2018-11-12
NZ627827A (en) 2016-02-26
JP2018127473A (ja) 2018-08-16
EA202190473A2 (ru) 2021-06-30
EA201290583A1 (ru) 2013-04-30
LT2932970T (lt) 2018-06-25
JP2017008087A (ja) 2017-01-12
HRP20150770T1 (hr) 2015-08-28
IL221007A (en) 2016-06-30
CA3060290A1 (en) 2011-08-04
CY2018029I2 (el) 2019-07-10
IL281959A (en) 2021-05-31
HUS1800042I1 (hu) 2018-11-28
US20150238496A1 (en) 2015-08-27
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
RS65183B1 (sr) 2024-03-29
ME03058B (me) 2019-01-20
US20180098992A1 (en) 2018-04-12
SG10201509476RA (en) 2015-12-30
CO6602152A2 (es) 2013-01-18
US20180200254A1 (en) 2018-07-19
LT3127542T (lt) 2018-11-26
CN105311033B (zh) 2019-05-07
US20170079982A1 (en) 2017-03-23
TR201807704T4 (tr) 2018-06-21
PT2531027E (pt) 2015-09-16
NZ601319A (en) 2014-08-29
ES2969969T3 (es) 2024-05-23
MA34002B1 (fr) 2013-02-01
NO2018036I1 (no) 2018-10-15
RS57323B1 (sr) 2018-08-31
EP3494972B1 (en) 2023-12-13
PH12016500195A1 (en) 2016-12-05
LTPA2018013I1 (lt) 2018-11-12
AU2011209788B2 (en) 2014-02-06
MY188334A (en) 2021-11-30
ECSP12012106A (es) 2013-05-31
PE20160180A1 (es) 2016-05-04
CY1120457T1 (el) 2019-07-10
PE20121524A1 (es) 2012-12-03
CA2967453C (en) 2018-07-17
LUC00090I2 (es) 2019-01-08
US20170119777A1 (en) 2017-05-04
MX367937B (es) 2019-09-12
PT3127542T (pt) 2018-11-26
EP2531027B1 (en) 2015-05-06
RS54123B1 (en) 2015-12-31
FR18C1043I2 (fr) 2019-10-11
US20160199379A1 (en) 2016-07-14
JP2013518107A (ja) 2013-05-20
CR20120423A (es) 2012-11-22
EP4316599A2 (en) 2024-02-07
SI2531027T1 (sl) 2015-08-31
KR101883750B1 (ko) 2018-07-31
SG182614A1 (en) 2012-08-30
FIC20240016I1 (fi) 2024-05-31
HRP20240168T1 (hr) 2024-04-26
PT3494972T (pt) 2024-02-12
SI3494972T1 (sl) 2024-03-29
KR20170078868A (ko) 2017-07-07
EP3494972A1 (en) 2019-06-12
CA3003988A1 (en) 2011-08-04
IL267658B (en) 2021-04-29
EP2531027A4 (en) 2013-07-03
ME02182B (me) 2015-10-20
SMT201500177B (it) 2015-09-07
US20160339033A1 (en) 2016-11-24
LT3494972T (lt) 2024-03-12
CY1121040T1 (el) 2019-12-11
NO2932970T3 (es) 2018-08-18
HK1209629A1 (en) 2016-04-08
CA2787691C (en) 2018-07-17
EP3127542B1 (en) 2018-08-22
US20200230147A1 (en) 2020-07-23
FR18C1043I1 (es) 2018-11-30
TN2012000376A1 (en) 2014-01-30
IL281959B (en) 2021-12-01
EP3127542A1 (en) 2017-02-08
PH12016500195B1 (en) 2016-12-05
KR101964923B1 (ko) 2019-04-02
DK2932970T3 (en) 2018-05-28
FI3494972T3 (fi) 2024-03-01
EA202190473A3 (ru) 2021-12-31
PH12018502489A1 (en) 2020-06-15
EP3351249A1 (en) 2018-07-25
AU2011209788C1 (en) 2014-08-28
IL267658A (en) 2019-08-29
KR101830715B1 (ko) 2018-04-04
BR112012018670A2 (pt) 2018-02-06
AU2011209788A1 (en) 2012-08-16
MX367938B (es) 2019-09-12
EA037601B1 (ru) 2021-04-20
DOP2012000205A (es) 2012-10-15
US20170281636A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
PH12018502489A1 (en) Antiviral therapy
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
MD4754B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
PH12015501156A1 (en) Pharmaceutical compositions
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
EP2555798A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSIONS
TW200738700A (en) HIV integrase inhibitors
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.